A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP STUDY OF PITAVASTATIN 4 MG VS. PRAVASTATIN 40 MG IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

Trial Profile

A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP STUDY OF PITAVASTATIN 4 MG VS. PRAVASTATIN 40 MG IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Pitavastatin (Primary) ; Pravastatin
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms PREVAIL-US
  • Sponsors Kowa Research Institute
  • Most Recent Events

    • 31 May 2012 Results were presented at the National Lipid Association's (NLA) Scientific Sessions in 2012.
    • 27 Mar 2012 Tolerability analysis presented at the 61st Annual Scientific Session of the American College of Cardiology.
    • 16 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top